04-1077 Anti-RelB (NT) Antibody, clone EP613Y, rabbit monoclonal

100 µL  
Retrieving price...
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
Request Pricing
Limited AvailabilityLimited Availability
In Stock 
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Special Offers


      Contact Customer Service

      Click To Print This Page


      Replacement Information

      Key Spec Table

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      HWB, ICC, IH(P), IPRbUnpurifiedMonoclonal Antibody
      Catalogue Number04-1077
      DescriptionAnti-RelB (NT) Antibody, clone EP613Y, rabbit monoclonal
      Alternate Names
      • reticuloendotheliosis viral oncogene homolog B
      • v-rel avian reticuloendotheliosis viral oncogene homolog B (nuclear factor of kappa light polypeptide gene enhancer in B-cells 3)
      • v-rel reticuloendotheliosis viral oncogene homolog B
      • v-rel reticuloendotheliosis viral oncogene homolog B,
        nuclear factor of kappa light polypeptide gene enhancer in -cells 3
      Background InformationNFĸB (Nuclear Factor kappa B) represents a group of transcription factors that are structurally related and evolutionarily conserved proteins related to the proto-oncogene c-Rel. The five members in mammals includes Rel (cRel), RelA (p65), RelB, NFĸB1 (p50 and its precursor p105), and NFĸB2 (p52 and its precursor p100) NFĸB/Rel proteins exist as homo- or heterodimer complexes.
      In a majority of unstimulated cells, the NFĸB transcription factors are bound to the inhibitory IĸB proteins and retained in the cytoplasm in their inactive form. Upon stimulation by multiple inducers, IĸBα is rapidly phosphorylated and degraded. This results in the release of the NFĸB complex to the nucleus.
      Product Information
      • Raji and Daudi cell lysate
      PresentationRabbit Monoclonal in buffer containing 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl containing 40% Glycerol, 0.01% sodium azide and 0.05% BSA.
      ApplicationPlease note that this product will not be available for sale after March 15, 2015. Please select one of the other antibodies against this target.
      Key Applications
      • Western Blotting
      • Immunocytochemistry
      • Immunohistochemistry (Paraffin)
      • Immunoprecipitation
      Application NotesImmunohistochemistry Analysis: A 1:100-250 dilution from a previous lot detected RelB in human ovarian carcinoma tissue.
      Immunocytochemistry Analysis: A 1:250-500 dilution from a previous lot worked in IC.
      Immunoprecipitation: A 1:50 dilution from a previous lot was used in IP.
      Biological Information
      ImmunogenSynthetic peptide corresponding to residues in near the N-term of human RelB.
      SpecificityThis antibody recognizes RelB at and around the N-terminus.
      Species Reactivity
      • Human
      Antibody TypeMonoclonal Antibody
      Entrez Gene Number
      Gene Symbol
      • I-REL
      • I-Rel
      • IREL
      Purification MethodUnpurified
      UniProt Number
      UniProt SummaryFUNCTION: NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49.
      SUBUNIT STRUCTURE: Component of the NF-kappa-B RelB-p50 complex. Component of the NF-kappa-B RelB-p52 complex. Self-associates; the interaction seems to be transient and may prevent degradation allowing for heterodimer formation with p50 or p52. Interacts with NFKB1/p50, NFKB2/p52 and NFKB2/p100. Interacts with NFKBID By similarity.
      INDUCTION: By mitogens.
      DOMAIN: Both N- and C-terminal domains are required for transcriptional activation.
      PTM: Phosphorylation at 'Thr-103' and 'Ser-573' is followed by proteasomal degradation By similarity.
      SEQUENCE SIMILARITIES: Contains 1 RHD (Rel-like) domain.
      CAUTION: Was originally (Ref.1) thought to inhibit the transcriptional activity of nuclear factor NF-kappa-B.
      Molecular Weight~70 kDa
      Physicochemical Information
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality AssuranceEvaluated by Western Blot on Raji and Daudi cell lysates.
      Western Blot Analysis: A 1:500 dilution of this antibody was used to detect RelB in Raji and Daudi cell lysates.
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsStable for 1 year at -20ºC from date of receipt.
      Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
      Note: Variability in freezer temperatures below -20°C may cause glycerol containing solutions to become frozen during storage.
      Packaging Information
      Material Size100 µL
      Transport Information
      Supplemental Information

      Related Products & Applications

      Related Products

      Catalogue Number Description  
      06-1105 Anti-RelB Antibody Show Pricing & Availability


      Life Science Research > Antibodies and Assays > Primary Antibodies